Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07210320) titled 'PK/PD Study of IN-001 Sublingual Spray in Healthy Adults' on Sept. 29.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Insignis Therapeutics, Inc.
Condition:
Type 1 Allergy
Anaphylaxis
Intervention:
Drug: Epinephrine Auto-Injector 0.3 mg/0.3 mL
Drug: Epinephrine 0.3 mg intramuscular manual injection via a syringe and needle
Drug: IN-001 9.06 mg Sublingual Spray
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: October 24, 2025
Target Sample Size: 30
C...